Cardiomyopathy cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Edzel Lorraine Co, DMD, MD[2]

The cost-effectiveness of different management options depends on the associated risk factors and risk for sudden cardiac death. Most patients with cardiomyopathies are treated similar to heart failure patients, although some do not respond well and might need heart transplantation eventually.

Template:WH Template:WS Template:Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy. Citation data: American heart journal, ISSN: 1097-6744, Vol: 154, Issu

Template:Impact of Advanced Therapies for Improving Survival to Heart Transplant in Patients with Hypertrophic Cardiomyopathy. Rowin EJ1, Maron BJ2, Abt P2, Kiernan MS3, Vest A3, Costantino F4, Maron MS2, DeNofrio D3: Am J Cardiol. 2018 Apr 15;121(8):986-996